Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 10 Sep 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer.
- 04 Jun 2019 Results assessing extended clinical follow-up and long-term molecular response data presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 31 Aug 2018 Biomarkers information updated